Sussan Nourshargh

TL;DR: In this paper, the authors validate the enzyme isoprenylcysteine carboxylmethyltransferase (ICMT) as a new therapeutic target for progeria with the development of a new series of potent inhibitors of this enzyme that exhibit an excellent antiprogeroid profile.

TL;DR: The results indicate that PAF is a vasoconstrictor in the rabbit pulmonary circulation and augmented responses occur with repeated injections at 60 min intervals, and PAF produces predominantly arteriolar constriction i.e. proximal to the site of leakage during forward perfusion.

TL;DR: The results suggest that the in vivo events leading to the accumulation of neutrophils in response to IL-1 alpha are rapidly initiated, as well as the species cross-reactivity of the antagonist.

TL;DR: Results support the potential use of UCM-13207 as a new treatment for progeria, a new potent inhibitor of isoprenylcysteine carboxylmethyltransferase that reduces progerin nuclear accumulation and ameliorates the typical alterations in progeroid human and mouse cells.

TL;DR: The results of this study indicate that PAF is not involved in neutrophil accumulation, eosinophil accumulation and oedema formation induced by LTB4, ZAP and a PCA reaction, but endogenous PAF does, however, appear to have a role in zymosan‐induced eosInophils accumulation but not neutrophIL accumulation, suggesting the existence of different inflammatory pathways in the induction of neutrophils and eos inophil collection in